AngioDynamics Receives Neutral Rating from Zacks (ANGO)
AngioDynamics (NASDAQ:ANGO)‘s stock had its “neutral” rating reaffirmed by Zacks in a report released on Friday. They currently have a $15.00 price objective on the stock. Zacks‘s price objective would indicate a potential upside of 6.01% from the stock’s previous close.
Zacks’ analyst wrote, “AngioDynamics’ fiscal 2014-fourth quarter earnings of $0.18 beat the Zacks Consensus Estimate by $0.06 and the year-ago earnings of $0.15 by 20%. Revenues of $94 million went up by 4.5% and were in line with the Zacks Consensus Estimate. The company introduced its fiscal 2015 earnings and revenue guidance. Significant turnaround in the Vascular Access business and success of the company’s BioFlo products boosted revenues. However, soft sales in the Supply Agreement business causes concern apart from the ongoing difficulties in the medical device industry. We reiterate our Neutral recommendation on AngioDynamics with a price target of $15.00.”
AngioDynamics (NASDAQ:ANGO) traded down 0.57% on Friday, hitting $14.07. 167,053 shares of the company’s stock traded hands. AngioDynamics has a 52-week low of $10.84 and a 52-week high of $19.00. The stock has a 50-day moving average of $15.08 and a 200-day moving average of $15.28. The company has a market cap of $492K and a price-to-earnings ratio of 160.80.
AngioDynamics (NASDAQ:ANGO) last released its earnings data on Wednesday, July 23rd. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.06. The company had revenue of $94.07 million for the quarter, compared to the consensus estimate of $93.65 million. During the same quarter in the previous year, the company posted $0.07 earnings per share. The company’s revenue for the quarter was up 4.5% on a year-over-year basis. Analysts expect that AngioDynamics will post $0.40 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on ANGO. Analysts at Raymond James reiterated an “outperform” rating on shares of AngioDynamics in a research note on Thursday. They now have a $17.00 price target on the stock, down previously from $18.00. Separately, analysts at Canaccord Genuity upgraded shares of AngioDynamics from a “hold” rating to a “buy” rating in a research note on Thursday, June 19th. They now have a $20.00 price target on the stock, up previously from $16.25.
AngioDynamics, Inc designs manufacture and sell a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.